Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionPrestige Wealth Management Group LLC
Latest Disclosed Ownership226 shares
Latest Disclosed Value $ 74,777
Prestige Wealth Management Group LLC reports 30.64% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - Prestige Wealth Management Group LLC filed a 13F-HR form disclosing ownership of 226 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $64,568 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 173 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 30.64% during the quarter. The current value of the position is $58,873 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 226 53 30.64 75 8.82 0.0144
2026-02-11 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 173 -11 -5.98 69 -18.07 0.0131
2026-02-20 2025-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 184 0 0.00 84 38.33 0.0162
2025-11-10 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 184 0 84 0.0162
2026-02-20 2025-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 184 -132 -41.77 60 -29.41 0.0122
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 184 -132 60 0.0122
2026-02-20 2025-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 316 0 0.00 85 14.86 0.0182
2025-05-12 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 316 0 85 0.0182
2026-02-20 2024-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 316 -135 -29.93 74 -40.32 0.0155
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 316 -135 74 0.0155
2026-02-20 2024-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 451 179 65.81 124 87.88 0.0256
2024-11-15 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 451 179 124 0.0256
2026-02-20 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 272 -200 -42.37 66 -5.71 0.0143
2024-08-06 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 272 -200 66 0.0143
2024-04-26 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 472 194 69.78 71 32.08 0.0152
2024-04-26 2023-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 278 -36 -11.46 53 -3.64 0.0121
2024-02-08 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 278 -36 53 0.0100
2024-04-26 2023-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 314 304 3,040.00 56 5,400.00 0.0137
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 314 304 56 0.0137
2024-04-26 2023-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 10 0 0.00 2 -50.00 0.0005
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10 0 2 0.0005
2024-04-26 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 10 3 42.86 2 100.00 0.0005
2023-05-16 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10 3 2 0.0005
2023-02-08 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7 -30 -81.08 2 -85.71 0.0004
2022-11-01 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37 -1,480 -97.56 7 -96.83 0.0020
2022-08-10 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,517 293 23.94 221 10.50 0.0599
2022-05-05 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,224 600 96.15 200 90.48 0.0492
2022-02-15 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 624 580 1,318.18 105 1,066.67 0.0251
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44 14 46.67 9 80.00 0.0023
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30 0 0.00 5 25.00 0.0013
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30 0 0.00 4 0.00 0.0011
2021-02-17 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30 0 0.00 4 0.00 0.0011
2020-10-26 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30 0 0.00 4 0.00 0.0012
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30 0 0.00 4 33.33 0.0014
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30 30 3 0.0013
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.